Angioedema risk of thrombolytics: an integrated assessment using disproportionality analysis of the USFDA adverse event reporting system, case reviews and meta-analysis.
Kannan Sridharan
✦ AI-curated · Sources linked
In 30 seconds
This integrated assessment examined angioedema associated with thrombolytic therapy and concomitant renin-angiotensin-aldosterone system inhibitors (RAAS-i), using USFDA adverse-event reports, case reviews, and a meta-analysis of observational studies. Disproportionality signals were identified for alteplase (ROR: 3.1) and tenecteplase (ROR 2.85), with stronger signals during RAAS-i co-administration. Across 24 studies (n = 3,007), RAAS-i use was associated with increased angioedema risk (OR: 3.12; 95% CI: 2.01-4.85). Reported mortality was comparable between thrombolytic monotherapy and combination therapy.
Key findings
- Meta-analysis of 24 studies (n = 3,007) found increased angioedema risk with RAAS-i use (OR: 3.12; 95% CI: 2.01-4.85).
- USFDA reports showed disproportionality signals for alteplase (ROR: 3.1) and tenecteplase (ROR 2.85), stronger with RAAS-i co-administration.
- Among 60 reviewed cases, 59 had orofacial angioedema within 3 hours; 16 required advanced airway management.
- Mortality rates were comparable between thrombolytic monotherapy and thrombolytic–RAAS-i combination therapy.
Why it matters
Angioedema can be life-threatening, and the reported association with RAAS-i co-administration highlights a potential safety concern during thrombolysis. The case review indicates that airway intervention may be needed in some cases. Awareness of this signal can inform risk assessment and monitoring, while the evidence does not establish that RAAS-i use causes angioedema.
What to keep in mind
The meta-analysis included observational studies, and the adverse-event reporting analysis is based on reports rather than a population denominator; these designs limit causal inference.